Literature DB >> 10465932

Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics.

A A Ding1, H Wu.   

Abstract

Recently, potent combination antiviral therapies consisting of reverse transcriptase inhibitor (RTI) drugs and protease inhibitor (PI) drugs, have been developed which can rapidly suppress HIV below the limit of detection. Two phases of plasma viral decay after initiation of treatment have been observed in clinical studies. Some researchers have suggested that the viral decay rates may reflect the potency (efficacy) of antiviral therapies. In this paper we model the effect of RTI drugs and PI drugs as inhibition rates of cell infection and infectious virus production, respectively, based on the biological mechanisms of these two different types of drugs. Through rigorous mathematical derivation, we show that the two viral decay rates are monotone functions of the treatment effects of these antiviral therapies. We derive approximation formulas for the relationships between viral decay rates and treatment effects. Computer simulations show that the approximation formulas approximate the true values very well. These formulas may be used to study what factors really affect the viral decay rates. The results in this paper provide a theoretical justification for using both viral decay rates for evaluation of the treatment efficacy of antiviral therapies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10465932     DOI: 10.1016/s0025-5564(99)00021-8

Source DB:  PubMed          Journal:  Math Biosci        ISSN: 0025-5564            Impact factor:   2.144


  15 in total

1.  HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing?

Authors:  R A Arnaout; M A Nowak; D Wodarz
Journal:  Proc Biol Sci       Date:  2000-07-07       Impact factor: 5.349

2.  Simultaneous Bayesian inference for linear, nonlinear and semiparametric mixed-effects models with skew-normality and measurement errors in covariates.

Authors:  Yangxin Huang; Ren Chen; Getachew Dagne
Journal:  Int J Biostat       Date:  2011-01-06       Impact factor: 0.968

3.  Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.

Authors:  Thi Huyen Tram Nguyen; Emmanuelle Comets; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-11       Impact factor: 2.745

4.  A Bayesian Approach in Differential Equation Dynamic Models Incorporating Clinical Factors and Covariates.

Authors:  Yangxin Huang
Journal:  J Appl Stat       Date:  2010-02-01       Impact factor: 1.404

5.  Mixed-Effects Models with Skewed Distributions for Time-Varying Decay Rate in HIV Dynamics.

Authors:  Ren Chen; Yangxin Huang
Journal:  Commun Stat Simul Comput       Date:  2014-06-23       Impact factor: 1.118

6.  Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy.

Authors:  J Mittler; P Essunger; G J Yuen; N Clendeninn; M Markowitz; A S Perelson
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

7.  Bayesian inference for skew-normal mixture models with left-censoring.

Authors:  Getachew A Dagne
Journal:  J Biopharm Stat       Date:  2013       Impact factor: 1.051

8.  Segmental modeling of changing viral load to assess drug resistance in HIV infection.

Authors:  H Liang
Journal:  Stat Methods Med Res       Date:  2007-08       Impact factor: 3.021

9.  Rapid human immunodeficiency virus decay in highly active antiretroviral therapy (HAART)-experienced children after starting mega-HAART.

Authors:  Nottasorn Plipat; Ping K Ruan; Terence Fenton; Ram Yogev
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.

Authors:  Sarah Palmer; Frank Maldarelli; Ann Wiegand; Barry Bernstein; George J Hanna; Scott C Brun; Dale J Kempf; John W Mellors; John M Coffin; Martin S King
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.